FHI 360-
REQUEST FOR CONSULTANT SERVICES PROPOSAL

FHI 360
REQUEST FOR CONSULTANT SERVICES PROPOSAL (RFP)

BACKGROUND
Pharmacokinetic (serum hormone levels) and pharmacodynamic (suppression of ovulation) evidence indicates that the 104 mg subcutaneous formulation of depot medroxyprogesterone acetate (DMPA-SC) provides contraceptive efficacy beyond three months. Extending the reinjection interval of DMPA-SC from 3 to 4 months would reduce long-term progestin exposure, potentially shorten the time to return to ovulation and fertility, and possibly reducing other dose-dependent side effects. Also, having one less injection each year would decrease programmatic costs and further facilitate access to DMPA-SC in resource-constrained settings.

With support from the Children’s Investment Fund Foundation (CIFF), FHI Partners is conducting several activities to establish the evidence base for and support the registration of a generic DMPA-SC as a 4-month product. The availability of such a product has the potential to improve consumer experience with a significantly lower dose, offer procurement savings that could grow to $10M per year, and alleviate supply chain bottlenecks faced with the current manufacture of Sayana® Press.

Understanding service delivery implications and user and provider preferences for and reactions to a 4-month product are key to the successful introduction of this new injectable. This scope of work (SOW) will support two research activities focused on market/service delivery implications (Activity 1) and user considerations (Activity 2) for the introduction of a 4-month DMPA-SC product in Nigeria.

You need to login to view the rest of the content. Please . Not a Member? Join Us
BID WRITING | PROPOSAL WRITING

Learn how our unique and professional approach to bid and proposal writing, gives you a much better chance of winning contracts. Learn How Here

Scroll to Top

FILL IN YOUR DETAILS TO CONTACT US; OR SIMPLY DIAL 08120020039